Tricuspid Valve Academic Research Consortium Definitions for Tricuspid Regurgitation and Trial Endpoints

TVARC Steering Committee

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations

Abstract

Interest in the pathophysiology, etiology, management, and outcomes of patients with tricuspid regurgitation (TR) has grown in the wake of multiple natural history studies showing progressively worse outcomes associated with increasing TR severity, even after adjusting for multiple comorbidities. Historically, isolated tricuspid valve surgery has been associated with high in-hospital mortality rates, leading to the development of transcatheter treatment options. The aim of this first Tricuspid Valve Academic Research Consortium document is to standardize definitions of disease etiology and severity, as well as endpoints for trials that aim to address the gaps in our knowledge related to identification and management of patients with TR. Standardizing endpoints for trials should provide consistency and enable meaningful comparisons between clinical trials. A second Tricuspid Valve Academic Research Consortium document will focus on further defining trial endpoints and will discuss trial design options.

Original languageEnglish
Pages (from-to)1711-1735
Number of pages25
JournalJournal of the American College of Cardiology
Volume82
Issue number17
DOIs
StatePublished - 24 Oct 2023

Keywords

  • transcatheter
  • treatment
  • tricuspid regurgitation

Fingerprint

Dive into the research topics of 'Tricuspid Valve Academic Research Consortium Definitions for Tricuspid Regurgitation and Trial Endpoints'. Together they form a unique fingerprint.

Cite this